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Introduction
The American Heart Association estimates that by 2035 over 130 million or 45.1 percent
of the American population is projected to have some form of cardiovascular disease, defined as
coronary heart disease, stable/unstable angina, heart failure and stroke. It is expected that the
total cost of treatment for patients with cardiovascular disease will reach 1.1 trillion by 2035
accordingly. Approximately 17.9 million deaths that were reported in 2016 were related to
cardiovascular disease based on the World Health Organization statistics. The American College
of Cardiology and American Heart Association suggest that primary prevention is accredited to
early identification of modifiable and nonmodifiable risk factors therefore, early recognition is
pivotal in decreasing all-cause morbidity and mortality of cardiovascular disease. Modifiable
risks factors such as diet, activity level, and smoking are often utilized as risk stratification for
cardiovascular risk; however, lipid profiles such as non-high-density lipoprotein (HDL) and lowdensity lipoprotein (LDL) remain at the forefront as a positive predictor of cardiovascular risk.
While it has been established that the proportion of HDL to LDL play an integral role in the
progression of cardiovascular disease, it also is thought that inflammation contributes in the
progression of coronary artery disease. The Centers for Disease Control and Prevention and the
American Heart Association concluded that it is reasonable to measure C-reactive protein (CRP)
a sensitive circulating biomarker of inflammation as an adjunct to the measurement of
established risk factors in order to better assess the risk of coronary heart disease.1
According to the study conducted by Dr. Edward T.H. Yeh Department of Cardiology,
University of Texas, approximately half of patients with an initial cardiovascular event did not
have any known risk factors.2 Currently medical professionals screen patients for risk factors to
identify opportunities for prevention, therefore, a novel risk factor such as C-reactive protein

1

may help identify patients at risk for cardiovascular disease (CVD). Current evidence suggests
that inflammatory biomarkers such as CRP have been shown to be just as effective in predictive
value for CVD in comparison to low-density lipoprotein.2
Background
CRP was originally discovered by Tillet and Francis in 1930. It reacted to
C polysaccharide of pneumococcus from which the name was derived. The formation of
atherosclerotic plaque is a very complex process that involves inflammatory mediators, lipid
formation and platelet dysfunction. C- reactive protein is an inflammatory mediator produced by
the liver that is elevated in the acute phase of inflammation. As a proinflammatory bio marker,
CRP is thought to increase the uptake of LDL by macrophages and enhance the local expression
of inflammatory mediators. While lipid deposition is the foundation in which atherogenic plaque
is formed, inflammatory mediators such as CRP have a distinct role in amplifying the
atherogenic cascade by activating interleukin-1(IL-1), interleukin-6 (IL-6) and tumor necrosis
factor alpha (TNFa), which contributes to the inflammatory damage that occurs to blood vessels.
CRP has been shown to inhibit nitric oxide production in the vessels, which can lead to
vasoconstriction and decreased compliance within vessels that may be occluded by plaque. It is
important to note that CRP exists in two distinct forms that are associated with very different
pathological processes. Pentameric CRP or (pCRP) does not induce thrombosis but does
contribute to plaque instability by increasing endothelial cell adhesion expression. Pentameric
CRP does have a less significant role in the amplification of inflammatory mediators in
comparison to monomeric CRP (mCRP). While monomeric CRP or mCRP does promote
thrombosis by amplification of the inflammatory cascade and is involved in the progression of
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cardiovascular disease. Therefore, monomeric CRP is involved with the large inflammatory
cascade that directly contributes to myocardial damage and infarct size.3
According to the article by Badimon, CRP Antithrombosis and Angiogenesis suggested
that increased levels of CRP are strongly predictive for the thrombotic complications of
atherosclerosis, and CRP may have a role in the risk stratification of patients with established
cardiovascular disease. In subjects with intermediate risk, incorporation of CRP to a model
assessment of cardiovascular risk improves the prognostic power for myocardial infarction
presentation and could help prevent one additional cardiovascular related death in 10 years with
400-500 patients screened. In patients with a previous history of CVD and in asymptomatic
subjects, high sensitivity-CRP (hs-CRP) was demonstrated to be a moderate predictor of
cardiovascular disease. In patients with stable and unstable angina elevated CRP levels are
predictive of future coronary events. Elevated CRP levels predicted heart failure and
cardiovascular mortality the year after the cardiovascular event. In patients with non-ST
elevation myocardial infarction in- hospital mortality was higher in patients with a CRP
greater than 10mg/L.3
Discussion
In the Reykjavik Study, initiated in 1967 as a prospective study of cardiovascular disease,
took a total of 8888 men and 9681 women without a history of cardiovascular disease born
between 1907 and 1934, and chronicled the subject’s medical history over the course of decades
until 1995. The study demonstrated that the decade to decade consistency for proinflammatory
markers such as CRP, and Erythrocyte Sedimentation Rate (ESR) as well as the platelet adhesion
protein known as von Willebrand factor yield similar predictive values in comparison to blood
pressure and total serum cholesterol concentration. This suggests that inflammatory markers
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may provide reliable data points in the long-term prediction of coronary heart disease.1 This
study further demonstrates that inflammatory biomarkers may play a role in the prediction of
cardiovascular disease.
The meta-analysis conducted by Li-ping He, Xin-yi Tang assessing early C- reactive
protein in the prediction of long-term outcomes after acute coronary syndromes, evaluated the
relation between early elevations of CRP after an acute coronary event and risk of adverse
outcomes. In this study which included 20 longitudinal studies comprising 2789 cases from a
population of 17,422 patients concluded that patients with higher CRP levels >10.0 (mg/l) after
acute coronary syndrome (ACS) were associated with 1.40-fold to 2.18-fold higher risk of
adverse outcomes as compared with patients with lower CRP levels.4 The resulting studies
demonstrate the correlation of elevated CRP levels and associated cardiovascular related events.
The Women’s Health study, a prospective case control study concluded that those with
the highest CRP levels had double the risk for developing cardiovascular disease. Of the patients
that subsequently developed a cardiovascular related event, nearly half of the subjects had LDL
levels < 130mg/dl, therefore suggesting that hs-CRP had a role in risk stratification. This study
further illustrated the correlation of higher hs-CRP levels in postmenopausal women who
subsequently had cardiovascular related events, compared to those that did not have elevated hsCRP levels. The study noted that of the 12 markers of inflammation that were highly correlated
to major adverse cardiovascular complications, hs-CRP was shown to be the most powerful
predictor of risk in the univariate analysis. Each of the markers of inflammation significantly
improved the usefulness of predicting risk, but models using both hs-CRP and lipid profiles were
better predictors of cardiovascular risk than were models that used only total cholesterol alone.
This data does support the notion that the incorporation of hs-CRP to the standard lipid screening
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may assist in the identification of patients at high risk for cardiovascular related events and
improve the primary prevention of interventions such as statin therapy.5

C- Reactive Protein in clinical practice
The incorporation of CRP in clinical practice may assist clinicians in the management of
patients with LDL values <160mg/dl that would normally be treated as moderate risk patients.
This could lead to more effective management and better outcomes as compared to the
traditional lipid measuring analysis. Lifestyle and dietary modifications may be an area that the
clinician may want to expound upon as CRP has also been shown to be elevated in patients that
were sleep restricted. The study conducted by Van Leeuwen et al. comparing patients that
habitually underwent sleep restriction of five days, produced elevated levels of IL-1, IL-6, IL-17
proinflammatory cytokines which are associated with increased expression of CRP. This study
correlates the link between sleep restriction and greater risk for CVD. As the increasing number
of patients with busy lifestyles continues, many patients in today’s society are constantly being
subjected to a sleep deprived state, having the science to educate patients on the risk of sleep
deprivation and the association with cardiovascular disease may benefit patients at risk and
potentially benefit from early intervention.6
The Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial
demonstrated similar findings to those of the Reversal of Atherosclerosis with Aggressive Lipid
Therapy trial ( REVERSAL) which established regression of atherosclerotic plaque when both
LDL and CRP were lowered , therefore postulating that there may be a decrease in
cardiovascular events if stain therapy is based not only LDL measures but CRP values as well.
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In addition, hs-CRP has been shown to predict vascular risk in patients undergoing percutaneous
coronary interventions and coronary bypass graft surgery. In patients with elevated hs-CRP that
had acute coronary syndromes were shown to have a poorer prognosis.7 The studies bring forth
new questions with regards to identifying other inflammatory markers as a means for
determining diagnostic and therapeutic adjuncts. While CRP may be strongly correlated to
cardiovascular disease, the biomarker may also be elevated in other inflammatory conditions
which would make the use of CRP as a screening tool more sensitive and less specific for
cardiovascular disease. Other limitations to note are many of the studies were conducted in
predominately homogenous patient populations, thereby providing very little insight on weather
CRP is a reliable predictor of CVD in minority groups. Other studies found that CRP may not be
a reliable predictor of cardiovascular disease in patients greater than 65 years of age in
comparison to traditional risk factors.8,9
Conclusion
CRP may be used as an adjunctive test to correlate cardiovascular risk in patients that are
suspected of having cardiovascular disease. Screening for lifestyle modifications will be
supportive in the prognosis and future outcomes in patients with cardiovascular disease. The
standard of care could be potentially influenced as preventative measures may be taken in
patients with low to moderate risk factors that demonstrate elevated CRP levels. Further
evidence is warranted in the development of screenings that carry a greater magnitude of
scientific backing demonstrating hs-CRP as potentially being used for risk stratification in
patients suspected of cardiovascular disease. Currently, the standard of care revolves around risk
modification and lipid management, however CRP may also serve as a diagnostic tool used in
the prevention of CVD resulting in better management of patients that are at risk for
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cardiovascular complications. The data compiled to date is compelling suggesting a greater
degree of research is necessary to establish screenings using hs-CRP as a mainstay of
preventative screening in comparison to non-HDL or other traditional risk factors such as
tobacco use and hypertension. Therefore, future areas of investigations are warranted in the
discovery of new inflammatory mediators linked to cardiovascular disease.
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